Pear Therapeutics (PEAR) reported Q1 EPS of ($0.17), $0.07 better than the analyst estimate of ($0.24). Revenue for the quarter came in at $2.7 million versus the consensus estimate of $2.4 million.
GUIDANCE:
Pear Therapeutics sees FY2022 revenue of $22 million.